ResMed (RMD) and QBE Insurance have attracted analyst attention heading into 2026, with both equities flagged for valuation reassessment. The piece suggests a forward-looking lens on these dual-sector plays—one spanning digital health and respiratory care, the other property and casualty insurance—reflecting portfolio construction shifts.
ResMed's inclusion signals continued focus on healthcare infrastructure and chronic disease management, where cloud-connected medical devices remain structurally relevant. QBE's presence indicates cyclical sensitivity to insurance underwriting cycles and premium rate dynamics in 2026, alongside potential macroeconomic headwinds affecting claims frequency and severity.
Valuation frameworks matter in a higher-for-longer rate environment; both companies face different pressures—ResMed on recurring revenue resilience and margin expansion, QBE on investment yield optimization and combined ratio discipline. This dual listing suggests analyst interest in relative-value positioning across defensive and cyclical healthcare/financial services segments.
Sector implication: The call reflects cautious positioning in Health Care and Financial Services, with emphasis on bottom-up stock selection rather than broad sector rotation. No macro catalyst is evident; this is opportunistic valuation work.